Britain's drug price watchdog, the National Institute for Health and Care Excellence (NICE), has given the go-ahead to GlaxoSmithKline's Tafinlar, which is among the new class of melanoma drugs that target tumor mutations. Not surprisingly, though, there's a catch: GSK must provide the drug at an undisclosed discount, according to NICE's guidance document announcing the decision.
When it comes to launching a next-generation drug, first is always best, right? Press releases can call it a "first-in-class" product. Sales and marketing teams can get a leg or two up on any follow-up rivals. What's not to like? McKinsey & Co. wanted to find out.
Analysts have been waiting--and waiting--for drugmakers to realize the growth they've predicted for the obesity market. And with a couple of pharma companies preparing to pony up R&D and marketing resources for their obesity products, it could finally be on the way.
Salix Pharmaceuticals, which has its hands full with a tax inversion merger and the integration of Santarus, will hand off Canadian sales of some of its drugs to India's Lupin. The package includes Salix's opioid constipation drug Relistor, a drug which has fallen far short of its initial potential.
Gilead Sciences has cracked the door on its pricing for the hepatitis C combo pill it's hoping to roll out next month. And here's the view: No "significant premium" to the current three-drug cocktail that includes Sovaldi, Gilead's current money-minting treatment.
Since 2007, the wholesale cost for a one-month supply of insulin product Humulin has gone from about $220 to approximately $1,200, MedPage Today reports.
Johnson & Johnson's next-gen prostate cancer pill, Zytiga, has been cruising since it hit the market back in April 2011, but now, it may be vulnerable to market share losses for the first time. The FDA has approved Medivation and Astellas' rival, Xtandi, for use in prostate cancer patients before chemo, giving the pill a head-to-head shot at J&J's blockbuster.
The pharma industry's free speech stand in a whistleblower lawsuit against Millennium Pharmaceuticals? Not so fast, says the Department of Justice. The First Amendment doesn't protect speech that spawns illegal conduct, federal prosecutors say in their own brief in the case.
Novo Nordisk may be nearing the regulatory finish line with an obesity-fighting dose of liraglutide, up for debate by the FDA's advisers this week.
Want a surefire way to shake up a drug market? Introduce new medication options that make it easier for patients to manage their disease. MS drugmakers would know; their market is all of a sudden...